普拉克索联合美多巴治疗帕金森病的疗效评价及其对生活质量的影响

Efficacy of pramipexole combined with medopa in treatment of Parkinson disease and its influence on quality of life

目的探究普拉克索联合美多巴治疗帕金森病的效果及其对患者生活质量的影响。方法选取某医院2016年5月-2018年11月收治的66例帕金森病患者作为研究对象,根据不同治疗方法随机分为参照组与研究组,参照组采用美多巴治疗,研究组采用美多巴联合普拉克索治疗,每组33例。观察两组治疗后帕金森评分量表评分以及生活质量评分。结果研究组的帕金森评分低于参照组,生活质量评分(93.47±5.66分)高于参照组(85.39±3.57分),差异具有统计学意义(P<0.05)。结论采用普拉克索联合美多巴治疗帕金森病患者效果显著,而且对改善患者的生活质量具有促进作用。

Objective To investigate the efficacy of pramipexole combined with medopa in the treatment of Parkinson disease(PD) and its influence on the quality of life(QOL) of the patients.Methods Sixty-six inpatients with PD in a hospital from May 2016 to November 2018 were selected and randomly divided into a control group(medopa) and a trial group(pramipexole combined with medopa) with 33 cases in each group.The Parkinson’s scores and QOL scores were observed after the treatment in two groups.Results The average Parkinson’s score of the trial group was lower than that of the control group,and the average QOL score of the trial group was higher than that of the control group(P<0.05).Conclusion Pramipexole combined with medopa is effective in the treatment of PD,and it can improve the QOL of the patients,and it is worth selecting.